In early Monday trading, shares of Amgen (AMGN) rose 0.9% after the company reported results from the VESALIUS-CV study. The data showed that its drug Repatha® (evolocumab) reduced the first major cardiovascular event by 25% and first myocardial infarction by 36% in high-risk patients with no prior events. These findings support broader application of PCSK9 inhibitors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.